АПИКСАБАН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ [PDF]
Атеротромбоз, 2015 Сердечно-сосудистые заболевания — наиболее распространенные патологии в России. Они обусловливают более 50% летальных случаев, значительная доля которых ассоциирована с развитием системных тромбоэмболий и инсульта.
О. О. Шахматов +1 more
doaj +6 more sources
АПИКСАБАН В ЛЕЧЕНИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: РАНДОМИЗИРОВАННЫЕ ИССЛЕДОВАНИЯ И ПОВСЕДНЕВНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА [PDF]
, 2017 Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
О. О. Шахматова +1 more
semanticscholar +3 more sources
Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases [PDF]
Качественная клиническая практика, 2023 Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients ...
A. S. Kolbin +2 more
doaj +3 more sources
CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN [PDF]
Атеротромбоз, 2015 The article presents the review of clinical studies that determined the role of apixaban in the early treatment and long-term secondary prophylaxis of deep vein thrombosis and lower limbs and and/or pulmonary arteries embolism.
I. S. Yavelov
doaj +3 more sources
Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation [PDF]
Качественная клиническая практика, 2023 Aim. To compare the effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (AF) for preventing stroke and systemic thromboembolism (embolism in the vessels of the systemic circulation, systemic embolism) in ...
A. S. Kolbin +2 more
doaj +3 more sources
Main indications for peroral anticoagulants: how to choose an optimal drug [PDF]
Качественная клиническая практика, 2018 Practical approaches to use of oral anticoagulants for prevention and treatment of thrombotic and thromboembolic complications in patients with atrial fibrillation, venous thromboembolism and coronary heart disease are considered.
I. S. Yavelov
doaj +2 more sources
Эффективность и безопасность апиксабана: что изменилось за 12 лет его использования в реальной клинической практике? [PDF]
, 2023 This review examines the position of apixaban among other direct oral anticoagulants in patients with atrial fibrillation (AF) and venous thrombosis in randomized clinical trials and real clinical practice.
E. Р. Panchenko +1 more
core +4 more sources
Хромогенный антиХа-тест: соотношение между единицами активности гепарина и концентрацией апиксабана и ривароксабана [PDF]
, 2020 Introduction. The direct oral anticoagulants (DOC) therapy does not require alaboratory control; however, it may be required to determine the anticoagulationlevel to choose a treatment strategy if alarge bleeding is developing or emergency surgery is ...
A. Dobrovolsky B. +3 more
core +4 more sources
Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных [PDF]
, 2021 Венозные тромбоэмболические осложнения (ВТЭО) — собирательное понятие, объединяющее тромбоз поверхностных вен, тромбоз глубоких вен, венозную гангрену и тромбоэмболию легочной артерии.
А. А. Трякин +9 more
core +6 more sources
Качественная клиническая практика, 2020 In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva +2 more
doaj +1 more source